Vosaroxin

Drug Profile

Vosaroxin

Alternative Names: AG-7352; AG-7352 hydrochloride; QINPREZO; SNS-595; SPC-595; Voreloxin

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Sunesis Pharmaceuticals; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Carboxylic acids; Naphthyridines; Pyrrolidines; Small molecules; Thiazoles
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute myeloid leukaemia; Ovarian cancer

Highest Development Phases

  • Preregistration Acute myeloid leukaemia
  • Phase I/II Myelodysplastic syndromes
  • Preclinical Glioblastoma
  • Discontinued Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 29 Nov 2016 Preclinical trials in Glioblastoma in USA (IV)
  • 29 Nov 2016 Pharmacokinetics and pharmacodynamics data from preclinical studies in Glioblastoma multiforme presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • 24 Aug 2016 Indiana University School of Medicine suspends enrolment in a pilot clinical study in Acute myeloid leukaemia (In the elderly, First line therapy, Combination therapy) in USA (NCT02485353)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top